指南与共识乳腺癌

ASCO指南更新:HER2阴性转移性乳腺癌化疗与靶向治疗

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
指南 / 共识 · J Clin Oncol · 2021-07-29

该指南更新了ASCO关于内分泌预处理后或激素受体阴性的HER2阴性转移性乳腺癌的化疗和靶向治疗推荐。专家组采用信号方法进行靶向系统文献综述,保留14篇文章,针对三阴性和HR阳性患者提出了免疫治疗、抗体药物偶联物、PARP抑制剂及单药化疗等推荐。

要点

  • PD-L1阳性三阴性MBC一线可化疗联合免疫检查点抑制剂。
  • PD-L1阴性三阴性MBC一线推荐单药化疗,危及生命可联合。
  • HR阳性MBC化疗时优选单药,内分泌进展后可内分泌±靶向或单药化疗。

核心结论

  • 对于三阴性和HR阳性HER2阴性MBC,指南根据生物标志物和治疗史推荐了免疫治疗、sacituzumab govitecan、PARP抑制剂及单药化疗等方案。

研究设计与样本

  • ASCO专家组采用信号方法进行靶向系统文献综述,检索并保留14篇文献,据此更新推荐。

主要发现

  • 专家组从文献综述中保留14篇文章,并据此修订了指南推荐。

关键数值与推荐

  • PD-L1阳性三阴性MBC一线可化疗联合免疫检查点抑制剂。
  • PD-L1阴性三阴性MBC一线推荐单药化疗而非联合化疗,危及生命时可联合。
  • 既往至少二线治疗的三阴性MBC可予sacituzumab govitecan。
  • 胚系BRCA突变且既往化疗的三阴性MBC可予PARP抑制剂而非化疗。
  • HR阳性HER2阴性MBC化疗时推荐单药而非联合,高症状或危及生命时可联合。

临床怎么用

  • 临床应根据PD-L1状态、胚系BRCA突变及既往治疗线数为HER2阴性MBC选择个体化方案。
  • 对于适合化疗的患者,优先考虑单药化疗,仅在危及生命或高症状时考虑联合方案。

局限性

  • 无法对患者何时应过渡到临终关怀或最佳支持治疗提出推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This guideline updates recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) that is either endocrine-pretreated or hormone receptor (HR)-negative. METHODS: An Expert Panel conducted a targeted systematic literature review guided by a signals approach to identify new, potentially practice-changing data that might translate into revised guideline recommendations. RESULTS: The Expert Panel reviewed abstracts from the literature review and retained 14 articles. RECOMMENDATIONS: Patients with triple-negative, programmed cell death ligand-1-positive MBC may be offered the addition of immune checkpoint inhibitor to chemotherapy as first-line therapy. Patients with triple-negative, programmed cell death ligand-1-negative MBC should be offered single-agent chemotherapy rather than combination chemotherapy as first-line treatment, although combination regimens may be offered for life-threatening disease. Patients with triple-negative MBC who have received at least two prior therapies for MBC should be offered treatment with sacituzumab govitecan. Patients with triple-negative MBC with germline BRCA mutations previously treated with chemotherapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy. Patients with HR-positive human epidermal growth factor receptor 2-negative MBC for whom chemotherapy is being considered should be offered single-agent chemotherapy rather than combination chemotherapy, although combination regimens may be offered for highly symptomatic or life-threatening disease. Patients with HR-positive MBC with disease progression on an endocrine agent may be offered treatment with either endocrine therapy with or without targeted therapy or single-agent chemotherapy. Patients with HR-positive MBC with germline BRCA mutations no longer benefiting from endocrine therapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy. No recommendation regarding when a patient's care should be transitioned to hospice or best supportive care alone is possible.Additional information is available at www.asco.org/breast-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Moy B, Rumble RB, Come SE, et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021. PMID: 34324366. doi:10.1200/JCO.21.01374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。